Physician profile
Reena John
NPI 1801042528
$4,898.91
in general payments reported to CMS, 2019-2025
34 companies · $825 in 2025
The $825 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,034 · 2022: $680 · 2023: $536 · 2024: $824 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,185.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,098.50 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $829.47 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $606.00 | 2021-2025 | |
| Novo Nordisk INC | $484.22 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $257.97 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $165.23 | 2021-2023 | |
| Pfizer INC. | $157.96 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.30 | 2021-2022 | |
| Lilly USA, LLC | $146.96 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.33 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $110.28 | 2025 | Isturisa |
| Glaxosmithkline, LLC. | $82.54 | 2021-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $82.40 | 2021-2022 | |
| Covis Pharma Gmbh | $58.71 | 2021 | |
| Astellas Pharma US INC | $46.53 | 2023-2024 | Veozah |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $45.10 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.69 | 2022 | |
| Daiichi Sankyo INC. | $37.97 | 2021-2025 | Injectafer |
| Boston Scientific Corporation | $30.88 | 2021 | |
| Ucb, INC. | $28.39 | 2022 | |
| Inogen, INC. | $27.94 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Redhill Biopharma INC. | $26.56 | 2023 | Movantik, Talicia, Aemcolo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.26 | 2022 | |
| Dexcom, INC. | $22.73 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $22.53 | 2021 | |
| Exact Sciences Corporation | $22.32 | 2025 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $22.22 | 2021 | |
| Impel Pharmaceuticals INC. | $21.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.76 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.82 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.44 | 2022 | |
| Radius Health, INC. | $17.01 | 2021 | |
| Merck Sharp & Dohme LLC | $16.95 | 2021 | |
| Nabriva Therapeutics, Plc | $16.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.